FR2763071B1 - Analogues peptidiques, et leurs utilisations notamment dans des compositions pharmaceutiques et pour le diagnostic - Google Patents

Analogues peptidiques, et leurs utilisations notamment dans des compositions pharmaceutiques et pour le diagnostic

Info

Publication number
FR2763071B1
FR2763071B1 FR9705677A FR9705677A FR2763071B1 FR 2763071 B1 FR2763071 B1 FR 2763071B1 FR 9705677 A FR9705677 A FR 9705677A FR 9705677 A FR9705677 A FR 9705677A FR 2763071 B1 FR2763071 B1 FR 2763071B1
Authority
FR
France
Prior art keywords
diagnosis
pharmaceutical compositions
peptide analogs
analogs
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9705677A
Other languages
English (en)
Other versions
FR2763071A1 (fr
Inventor
Jean Gerard Guillet
Gilles Guichard
Marina Ostankovitch
Francine Connan
Anne Quesnel
Jeannine Choppin
Jean Paul Briand
Sylviane Muller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9506703&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR2763071(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Priority to FR9705677A priority Critical patent/FR2763071B1/fr
Priority to CA002289110A priority patent/CA2289110A1/fr
Priority to EP98924401A priority patent/EP0984985A2/fr
Priority to PCT/FR1998/000923 priority patent/WO1998050423A2/fr
Publication of FR2763071A1 publication Critical patent/FR2763071A1/fr
Application granted granted Critical
Publication of FR2763071B1 publication Critical patent/FR2763071B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
FR9705677A 1997-05-07 1997-05-07 Analogues peptidiques, et leurs utilisations notamment dans des compositions pharmaceutiques et pour le diagnostic Expired - Fee Related FR2763071B1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
FR9705677A FR2763071B1 (fr) 1997-05-07 1997-05-07 Analogues peptidiques, et leurs utilisations notamment dans des compositions pharmaceutiques et pour le diagnostic
CA002289110A CA2289110A1 (fr) 1997-05-07 1998-05-07 Analogues peptidiques et leurs utilisations notamment dans des compositions pharmaceutiques et pour le diagnostic
EP98924401A EP0984985A2 (fr) 1997-05-07 1998-05-07 Analogues peptidiques et leurs utilisations notamment dans des compositions pharmaceutiques et pour le diagnostic
PCT/FR1998/000923 WO1998050423A2 (fr) 1997-05-07 1998-05-07 Analogues peptidiques et leurs utilisations notamment dans des compositions pharmaceutiques et pour le diagnostic

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9705677A FR2763071B1 (fr) 1997-05-07 1997-05-07 Analogues peptidiques, et leurs utilisations notamment dans des compositions pharmaceutiques et pour le diagnostic

Publications (2)

Publication Number Publication Date
FR2763071A1 FR2763071A1 (fr) 1998-11-13
FR2763071B1 true FR2763071B1 (fr) 2003-05-16

Family

ID=9506703

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9705677A Expired - Fee Related FR2763071B1 (fr) 1997-05-07 1997-05-07 Analogues peptidiques, et leurs utilisations notamment dans des compositions pharmaceutiques et pour le diagnostic

Country Status (4)

Country Link
EP (1) EP0984985A2 (fr)
CA (1) CA2289110A1 (fr)
FR (1) FR2763071B1 (fr)
WO (1) WO1998050423A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9090673B2 (en) 2003-12-12 2015-07-28 City Of Hope Synthetic conjugate of CpG DNA and T-help/CTL peptide
ES2490915B1 (es) * 2011-09-12 2015-09-17 Laboratorios Del Dr. Esteve, S.A. Método para monitorizar las respuestas de linfocitos T citotóxicos (LTC) mediante una reacción de hipersensibilidad de tipo retardado usando epítopos de LTC definidos

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8305491A (en) * 1990-08-01 1992-03-02 Cytel Corporation Novel immunosuppressant peptides
JPH06501961A (ja) * 1991-08-26 1994-03-03 日本たばこ産業株式会社 免疫調節活性を有するシユードペンタペプチド
CN1091138A (zh) * 1992-08-27 1994-08-24 迪金研究有限公司 疫苗
AUPM411994A0 (en) * 1994-02-25 1994-03-24 Deakin Research Limited Epitopes
FR2717081B1 (fr) * 1994-03-14 1996-06-21 Centre Nat Rech Scient Rétropeptides, anticorps dirigés contre ces derniers, et leurs utilisations pour la vaccination et le diagnostic in vitro.
CA2188432C (fr) * 1994-04-22 2011-02-01 Yutaka Kawakami Antigenes du melanome
AU6100196A (en) * 1995-06-06 1996-12-24 Igen, Inc. Peptide analogs and their use as haptens to elicit catalytic antibodies
CA2249390C (fr) * 1996-03-19 2007-12-18 University Of Virginia Patent Foundation Peptides reconnus par des lymphocytes cytotoxiques specifiques du melanome restreints par a1, a2 et a3, leurs utilisations
ZA975858B (en) * 1996-07-11 1998-09-01 Akzo Nobel Nv Melanoma associated peptide analogues and vaccines against melanoma

Also Published As

Publication number Publication date
WO1998050423A2 (fr) 1998-11-12
CA2289110A1 (fr) 1998-11-12
FR2763071A1 (fr) 1998-11-13
WO1998050423A3 (fr) 1999-08-19
EP0984985A2 (fr) 2000-03-15

Similar Documents

Publication Publication Date Title
TR199902529T2 (xx) Etkinle�tirilmi� protein C form�lasyonlar�.
EE200000395A (et) Peroraalne farmatseutiline pulseeriva vabanemisega annusvorm
EE9700241A (et) Farmatseutiline kompositsioon transdermaalseks manustamiseks
FR2732967B1 (fr) 1-phenylpyrazole-3-carboxamides substitues, actifs sur la neurotensine, leur preparation, les compositions pharmaceutiques en contenant
DE69910186D1 (de) Pharmazeutische zusammensetzung von topiramate
MA26553A1 (fr) Alpha-aryl-n-alkylnitrones et compositions pharmaceutiques contenant ceux-la
DE69512685T2 (de) Mittel zur verabreichung von wirksubstanzen an bzw. durch die haut
DZ2509A1 (fr) Analogues peptidiques de la lh-rh leur utilisationet les compositions pharmaceutiques les contenant.
IT8847693A0 (it) Fenil carbammato farmacologicamente attivo, suo procedimento di preparazione e composizione farmaceutica che lo contiene
ATE345133T1 (de) Laktose-freie, nicht-hygroskopische und wasserfreie pharmazeutische zusammensetzungen von descarboethoxyloratadin
IS2004B (is) Lyfjasamsetningar sem innihalda vorikónasól
DK0941075T3 (da) Smagsmaskerende farmaceutisk doseringsform med hurtig frigivelse
FR2774687B1 (fr) Lipopeptides contenant un fragment de l'interferon gamma, et leur utilisation dans des compositions pharmaceutiques
HUP0002490A2 (hu) Csersav-polimer kompozíciók gyógyászati anyagok szabályozott leadására, különösen a szájüregben
PL346764A1 (en) New oral formulation for 5-ht4
DE69301356D1 (de) Übersättigte topische zusammensetzungen
NO20006646L (no) Aminosyrederivater og legemidler inneholdende de samme som aktiv bestanddel
HK1029928A1 (en) Pharmaceutical compositions of peptides having lowsolubility in physiological medium.
FR2717081B1 (fr) Rétropeptides, anticorps dirigés contre ces derniers, et leurs utilisations pour la vaccination et le diagnostic in vitro.
FR2763071B1 (fr) Analogues peptidiques, et leurs utilisations notamment dans des compositions pharmaceutiques et pour le diagnostic
MY108692A (en) Topical composition
DE69831737D1 (de) Neurotrypsin
IT8621097A1 (it) Derivato di timo attivo per via orale, procedimenti per la sua preparazione e relative composizioni farmaceutiche
MA26604A1 (fr) Compositions pharmaceutiques.
FR2659556B1 (fr) Compositions a base d'arnica, et leurs utilisations notamment dans des compositions pharmaceutiques ou cosmetiques.

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20090119